IN2012DN00719A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN00719A IN2012DN00719A IN719DEN2012A IN2012DN00719A IN 2012DN00719 A IN2012DN00719 A IN 2012DN00719A IN 719DEN2012 A IN719DEN2012 A IN 719DEN2012A IN 2012DN00719 A IN2012DN00719 A IN 2012DN00719A
- Authority
- IN
- India
- Prior art keywords
- compounds
- disorders
- compositions
- useful
- cftr
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 5
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 abstract 4
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000030761 polycystic kidney disease Diseases 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 208000031513 cyst Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000037427 ion transport Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Provided herein are pyrimido-pyrrolo-quinoxalinedione (PPQ) compounds, and compositions comprising these compounds, that inhibit cystic fibrosis transmembrane conductance regulator (CFTR) mediated ion transport and that are useful for treating diseases and disorders associated with aberrantly increased CFTR chloride channel activity. The compounds, and compositions comprising the compounds, described herein are useful for treating diseases, disorders, and sequelae of diseases, disorders, and conditions that are associated with aberrantly increased CFTR activity, for example, polycystic kidney disease. The compounds may be used for inhibiting expansion or preventing formation of cysts in persons who have polycystic kidney disease.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23274109P | 2009-08-10 | 2009-08-10 | |
| PCT/US2010/045052 WO2011019737A1 (en) | 2009-08-10 | 2010-08-10 | Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN00719A true IN2012DN00719A (en) | 2015-06-19 |
Family
ID=43586433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN719DEN2012 IN2012DN00719A (en) | 2009-08-10 | 2010-08-10 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8609661B2 (en) |
| EP (1) | EP2464354B1 (en) |
| CN (1) | CN102695510A (en) |
| CA (1) | CA2769847C (en) |
| IN (1) | IN2012DN00719A (en) |
| WO (1) | WO2011019737A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE48842E1 (en) * | 2011-05-27 | 2021-12-07 | The Regents Of The University Of California | Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor |
| US20140171417A1 (en) * | 2012-12-19 | 2014-06-19 | Novartis Ag | Tricyclic compounds |
| BR112015014433A2 (en) * | 2012-12-19 | 2017-07-11 | Novartis Ag | tricyclic compounds |
| GB201905711D0 (en) * | 2019-04-24 | 2019-06-05 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases |
| CN114948966B (en) * | 2022-04-27 | 2023-06-20 | 南京鼓楼医院 | Application of a small molecule inhibitor in the preparation of drugs for treating multiple sclerosis and sepsis |
| CN115998763A (en) * | 2023-01-17 | 2023-04-25 | 暨南大学 | Application of chloride ion and compound targeting chloride ion channel in regulation and control of iron death |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2751969B1 (en) * | 1996-08-01 | 1998-12-04 | Centre Nat Rech Scient | CFTR CHANNEL ACTIVATING COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| GB9626643D0 (en) * | 1996-12-21 | 1997-02-12 | Astra Pharma Prod | Compounds |
| US7235573B2 (en) | 2002-09-30 | 2007-06-26 | The Regents Of The University Of California | Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors |
| DE602004022819D1 (en) * | 2003-06-06 | 2009-10-08 | Vertex Pharma | TRANSPORTER OF ATP-BINDING CASSETTE |
| FR2861304B1 (en) * | 2003-10-23 | 2008-07-18 | Univ Grenoble 1 | CFTR CHANNEL MODULATORS |
| AU2005228685B2 (en) | 2004-03-30 | 2010-08-19 | The Regents Of The University Of California | Hydrazide-containing CFTR inhibitor compounds and uses thereof |
| WO2006068928A1 (en) * | 2004-12-20 | 2006-06-29 | Wyeth | Pyrrolo[1,2-a]quinoxalin-5-(4h)-yl)sulfonyls and carbonyls and their use as estrogenic agents |
| KR20100016073A (en) * | 2007-04-02 | 2010-02-12 | 인스티튜트 포 원월드 헬스 | Cftr inhibitor compounds and uses thereof |
| WO2009076593A1 (en) | 2007-12-13 | 2009-06-18 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| AU2009228307A1 (en) | 2008-03-25 | 2009-10-01 | The Regents Of The University Of California | Water soluble small molecule inhibitors of the cystic fibrosis transmembrane conductance regulator |
| US20090253799A1 (en) | 2008-04-04 | 2009-10-08 | The Regents Of The University Of California | Divalent hydrazide compound conjugates for inhibiting cystic fibrosis transmembrane conductance regulator |
| USRE48842E1 (en) | 2011-05-27 | 2021-12-07 | The Regents Of The University Of California | Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor |
-
2010
- 2010-08-10 EP EP10808643.0A patent/EP2464354B1/en active Active
- 2010-08-10 CA CA2769847A patent/CA2769847C/en active Active
- 2010-08-10 CN CN2010800427350A patent/CN102695510A/en active Pending
- 2010-08-10 US US13/389,898 patent/US8609661B2/en active Active
- 2010-08-10 IN IN719DEN2012 patent/IN2012DN00719A/en unknown
- 2010-08-10 WO PCT/US2010/045052 patent/WO2011019737A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| EP2464354B1 (en) | 2015-04-01 |
| CN102695510A (en) | 2012-09-26 |
| WO2011019737A1 (en) | 2011-02-17 |
| EP2464354A1 (en) | 2012-06-20 |
| CA2769847C (en) | 2019-01-08 |
| US8609661B2 (en) | 2013-12-17 |
| EP2464354A4 (en) | 2013-03-27 |
| CA2769847A1 (en) | 2011-02-17 |
| US20120208822A1 (en) | 2012-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN00719A (en) | ||
| MX2010010343A (en) | Water soluble small molecule inhibitors of the cystic fibrosis transmembrane conductance regulator. | |
| WO2007129226A3 (en) | Use of syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders | |
| WO2008097561A8 (en) | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | |
| WO2006088888A3 (en) | Aptamer therapeutics useful in the treatment of complement-related disorders | |
| WO2008154251A3 (en) | C3b antibodies and methods for the prevention and treatment of complement- associated disorders | |
| WO2008147797A3 (en) | Ion channel modulators and methods of use | |
| TW200604192A (en) | Compounds and methods for inhibiting mitotic progression | |
| MY172151A (en) | Certain chemical entities, compositions and methods | |
| HK1206726A1 (en) | Imidazotriazinone compounds | |
| WO2009023509A3 (en) | Therapeutic combinations useful in treating cftr related diseases | |
| WO2008137633A3 (en) | Methods of modulating cellular homeostatic pathways and cellular survival | |
| WO2007064857A3 (en) | Amphoteric liposome formulation | |
| MX2012001156A (en) | Trisubstituted boron-containing molecules. | |
| EP2134736A4 (en) | Five- and six-membered conformationally locked 2',4'- carbocyclic ribo-thymidines for the treatment of infections and cancer | |
| WO2010059004A3 (en) | Chemical inhibitor of p53-snail binding and pharmaceutical composition for treating cancer disease containing same as its active ingredient | |
| EA201071248A1 (en) | DESIGNED PHTHALASINE ANTAGONISTS WAYS HEDGEHOG | |
| IL190632A0 (en) | Biphenyl derivatives and pharmaceutical compositions containing the same | |
| WO2008095086A3 (en) | Topiramate plus naltrexone for the treatment of addictive disorders | |
| WO2009146144A3 (en) | Divalent hydrazide compound conjugates for inhibiting cystic fibrosis transmembrane conductance regulator | |
| IN2012DN02471A (en) | ||
| WO2010009478A3 (en) | Compositions and methods for treating disorders associated with overweight animals | |
| WO2008144223A3 (en) | Triazolyl aminopyrimidine compounds | |
| WO2012158672A3 (en) | Compounds for use in treatment of mucositis | |
| WO2009158374A3 (en) | Inhibitors of akt activity |